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Abstract
MicroRNAs (miRNAs) are small 21–24 nucleotide RNAs that are capable of regulating multiple 
signaling pathways across multiple tissues. MicroRNAs are dynamically regulated and change in 
expression levels during periods of early development, tissue regeneration, cancer, and various 
other disease states. Recently, microRNAs have been isolated from whole serum and muscle 
biopsies to identify unique diagnostic signatures for specific neuromuscular disease states. 
Functional studies of microRNAs in cell lines and animal models of neuromuscular diseases have 
elucidated their importance in contributing to neuromuscular disease progression and pathologies. 
The ability of microRNAs to alter the expression of an entire signaling pathway opens up their 
unique ability to be used as potential therapeutic entry points for the treatment of disease. Here, 
we will review the recent findings of key microRNAs and their dysregulation in various 
neuromuscular diseases. Additionally, we will highlight the current strategies being used to 
regulate the expression of key microRNAs as they have become important players in the clinical 
treatment of some of the neuromuscular diseases.
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Introduction
MicroRNAs were first identified as anti-sense RNAs in C. elegans that were capable of 
regulating the expression levels of proteins by directly binding to the 3'UTR (untranslated 
region) of their complementary mRNA target [1]. Mammalian microRNAs were soon 
quickly identified and classified based on their sequence homology with known C. elegans 
microRNAs [2–4]. Improvements in whole-genome, next-generation sequencing 
technologies, and large scale transcriptome profiling have led to a subsequent identification 
and classification of mammalian microRNAs at a rapid rate starting in the mid to late-2000 s 
[5, 6]. Parallel computational methods and software algorithms have been developed which 
allow for the prediction of microRNA target genes in mammals [7–9].
Early gain and loss-of-function microRNA experiments demonstrated that microRNAs have 
significant roles in the regulation of protein function in many mammalian processes such as 
cancer, immune regulation, and cardiac function [10–13]. Interestingly, several of the early 
microRNAs identified as having significant roles in cardiac development and function, also 
had significant enrichment in expression in skeletal muscles [14, 15]. Large-scale 
microRNA microarray platforms identified microRNAs that were uniquely expressed and 
dysregulated in a variety of different human neuromuscular diseases [16]. Serum microRNA 
profiling of various neuromuscular diseases also revealed a similar dysregulation of 
particular microRNAs, and a unique diagnostic signature dependent on the mutation of the 
specific gene such as dystrophin [17, 18].
MicroRNAs as biomarkers and therapeutic entry points for treatment of muscle disease
An area of microRNA biology that has gained a lot of recent attention is the ability of 
microRNAs to circulate in the bloodstream via exosomes. MicroRNAs can be secreted from 
one tissue type and be transported to more distal tissues after being incorporated in multi-
vesicular bodies derived from the plasma membrane of cells. It remains unclear whether or 
not the distal (or target) tissues that incorporate these microRNA-containing exosomes 
function to inhibit target mRNAs, but this remains an active area of research. Nevertheless, 
the isolation and identification of specific miRNAs from these exosomes can reveal a 
significant shift towards a diseased state (Fig. 1A).
Serum profiling of microRNAs from neuromuscular diseases has revealed that specific 
microRNAs are indeed dysregulated in expression levels in a disease-dependent fashion 
(Table 1). MicroRNAs isolated from the serum of patients with Duchenne muscular 
dystrophy revealed that specific muscle-enriched microRNAs were significantly altered in 
expression dependent on the progression of the dystrophic disease pathology [18]. Similar 
results were observed in dystrophic mdx mouse muscles, which revealed that one particular 
muscle-enriched microRNA, miR-206, was significantly increased in expression levels when 
compared with normal mouse muscles [19].
MicroRNAs represent a unique therapeutic entry point for disease as a single microRNA can 
regulate multiple signaling pathways rather than the classical one gene, one target approach. 
Thus, several pharmaceutical and biotech companies have begun to develop microRNA-
based therapies for the treatment of disease in addition to using them as clinical biomarkers 
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of disease states [20, 21]. Recently, a miR-122 locked nucleic acid (LNA)-inhibitor, 
Miravirsen (SPC3649), has shown therapeutic efficacy and benefit in blocking hepatitis C 
(HCV) viral replication in phase 2a clinical trials [22]. Additionally, it has been 
demonstrated that manipulation of microRNAs using mouse models of neuromuscular 
diseases can ameliorate some of the disease pathologies associated with changes in the 
expression levels of specific microRNAs [23–26]. Given the broad reaching applications of 
microRNAs as both molecular biomarkers and therapeutic entry points, it is likely that 
microRNAs will become key mediators in the identification and treatment of patients with 
neuromuscular diseases. For example, a patient with an identified neuromuscular pathology 
and showing symptoms of a particular type of neuromuscular disease, but no mutation in the 
causative gene for that particular disease may have their blood drawn and microRNA 
profiled for diagnostic purposes to identify or exclude a particular disease with a defined 
microRNA signature (Fig. 1A). One could also apply an appropriate therapeutic course of 
intervention to a particular group of patients and use the microRNA signature as a biomarker 
to see if the dysregulated microRNAs return to more normal levels (Fig. 1B).
MicroRNAs are dynamically regulated in many muscle diseases
Duchenne muscular dystrophy (DMD)—One of the most studied neuromuscular 
diseases with significant microRNA dysregulation is Duchenne muscular dystrophy (DMD) 
[27]. Patients with mutations in the DMD gene that result in the loss of the large dystrophin 
protein isoform (Dp427) show loss of ambulation, severe muscle degeneration, and heart 
disease [28]. MicroRNA microarray profiling of dystrophin-deficient muscles from human 
patient biopsies revealed a unique signature of dysregulated muscle-enriched microRNAs 
when compared to other muscular dystrophies [16]. Follow-up studies in muscles of 
dystrophin-deficient mdx mice demonstrated that many microRNAs that regulate nNOS 
signaling, with a particular dysregulation of miR-1, miR-133a/b, and miR-206 (also referred 
to as “myomiRs”), were significantly altered by the loss of a functional dystrophin protein 
[29, 30]. MyomiRs (a term coined by combining myo/muscle and miR/microRNA) was used 
to originally describe three microRNAs (miR-1, miR-133a/b, and miR-206) that showed 
enriched expression in heart and skeletal muscles; but has since expanded from its original 
definition to include several additional microRNAs that are strongly expressed in muscle 
lineages [31, 32]. Profiling of human DMD patient myoblasts confirmed the dysregulation 
of miR-1, but also found a significant dysregulation in the expression of miR-29a both of 
which regulate a Dystrophin-nNOS-Hdac2 pathway [33]. Serum profiling of human patients 
revealed that the three muscle-enriched myomiR microRNAs were also dysregulated in both 
human patients and mdx mice [17, 18, 34, 35]. MicroRNA expression profiling of the serum 
from the dystrophic CXMDJ canine dystrophin-deficient model also showed a dysregulation 
of miR-1, miR-133a, and miR-206 [36]. Another recent study of serum obtained from DMD 
boys demonstrated that in addition to the three myomiRs (miR-1, miR-133a/b, and 
miR-206) being increased in expression, two other muscle-enriched microRNAs, miR-208b 
and miR-499 were also increased in expression [37] (Table 1). Another microRNA, miR-31, 
was shown to be significantly increased in DMD muscle, and might play a role in normal 
muscles in the regulation of the dystrophin protein levels via binding to its 3'UTR [38]. 
(Table 1). A more broadly expressed microRNA, miR-199a, was also shown to be induced in 
DMD muscle biopsies due to a transcriptional activation of its promoter via the myogenic 
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factor serum response factor (SRF) [39]. It has also been demonstrated that the muscle-
enriched microRNA, miR-486, is significantly decreased in expression in DMD patient 
muscle biopsies and myoblast cell lines, but not in the milder Becker muscular dystrophy 
(BMD) in which a partially functional dystrophin protein is produced [40]. Thus, it can be 
concluded that many microRNAs that are enriched in expression in skeletal muscle appear to 
be strongly dysregulated in Duchenne muscular dystrophy.
The functional roles of these muscle-enriched dysregulated DMD microRNAs (or 
“dystromiRs” as they are sometimes referred to as), lead to functional studies in mouse and 
muscle cell culture models [18]. These microRNAs (miR-1, miR-133a/b, and miR-206) 
were first given the classification as “dystromiRs” as potential diagnostic markers due to 
their dysregulation in dystrophin-deficient mdx mouse and human DMD patient skeletal 
muscles [17]. Global loss of both copies of miR-1 (miR-1-1 and miR-1-2) in mice revealed 
an essential function for miR-1 in postnatal cardiac conduction function, sarcomere 
formation, and activation of smooth muscle gene expression [41, 42]. Similar global deletion 
of both copies of miR-133a (miR-133a-1 and miR-133a-2) revealed an essential role for 
miR-133a in postnatal cardiac function, normal cardiomyocyte proliferation, and activation 
of SRF-dependent smooth muscle gene transcription [43]. Compound deletions of miR-1-1/
miR-133a-2 and miR-1-2/miR-133a-1, which in mammals are clustered and transcribed at 
the same genomic locus, revealed a role for these microRNAs as a regulator of smooth 
muscle gene transcription via suppression of the SRF cofactor myocardin [44]. The muscle 
enriched microRNA, miR-206, has been shown to be overexpressed in dystrophic and 
regenerating skeletal muscle samples along with serum from dystrophic patients and animals 
[16, 18, 45, 46]. Surprisingly, mice lacking miR-206 showed no overt skeletal muscle or 
cardiac phenotypes, which has led to the speculation that another microRNA may be playing 
a compensatory role in its absence [47].
A significant number of muscle diseases including DMD have elevated levels of microRNAs 
associated with fibrosis. One induced microRNA greatly associated with the fibrotic 
response in skeletal muscle disease is miR-21. MicroRNA-21 activation is strongly 
correlated with proliferation of fibroblasts and activation of TGFβ signaling in several 
models of fibrotic-associated diseases such as idiopathic pulmonary fibrosis (IPF) [48]. 
MicroRNA-21 is strongly induced in expression in DMD biopsies and is thought to be 
regulated by plasminogen activator inhibitor-1 (PAI-1) [16, 26]. PAI-1 is a key regulator of 
the extracellular matrix (ECM) and fibrotic response in mdx mouse muscles [26, 49]. 
Interestingly, miR-21 global knockout mice are viable and have reduced tumorigenic 
capacity in several non-muscle cell cancers due to an induction of the inhibitors of the 
Ras/MEK/ERK signaling pathways that normally repressed by miR-21 function [50, 51]. 
MicroRNA-21 was also shown to be significantly increased in expression in rodent models 
of myocardial disease, and activate ERK/MAPK signaling pathways in cardiac fibroblasts 
[52]. However, it is important to note that miR-21 global knockout mice showed the same 
stress-dependent cardiac remodeling that occurred in wild type control mice, suggesting that 
miR-21 inhibitor molecules might not have significant beneficial effects on myocardial 
disease pathologies [53]. Additionally, endothelial cell-specific miR-21 knockout mice 
showed significant vasculature remodeling concomitant with a reduction of collagen and 
other ECM proteins [54]. Conversely, overexpression of miR-21 in gain-of-function mouse 
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models results in a tissue-specific promotion tumorigenesis and cell proliferation [55]. 
Administration of TGFβ inhibitors in mdx mice subsequently blocks fibrosis and decreases 
miR-21 expression levels, thus making miR-21 both an important regulator of the dystrophic 
disease pathology and a useful biomarker for fibrotic response in muscle disease [56].
Facioscapulohumeral muscular dystrophy (FSHD)—Facioscapulohumeral muscular 
dystrophy (FSHD) is generally considered to be caused by the contraction of D4Z4 repeats 
subsequently leading to the activation of a transcription factor DUX4 in skeletal muscle [57, 
58]. More recently mutations in the chromatin remodeling factor SMCHD1 have been 
shown to affect DUX4 expression and distinguish FSHD Type 1 from FSHD Type 2[59]. 
The dynamic regulation of the expression of DUX4 and its transcriptional regulation have 
highlighted significant dysregulation of microRNAs during FSHD disease progression [60, 
61]. The overexpression of microRNA-411 in FSHD myoblasts has been implicated as a 
potential mechanism for the blocking of myogenic differentiation via directly suppressing 
YAF2 and YY1 transcriptional function [62]. Full transcriptome analysis of microRNAs 
dysregulated in FSHD myoblasts and serum from FSHD patients revealed a significant 
increase in expression of the muscle myomiRs (miR-1, miR-133a/b, miR-206) along with 
significant dysregulation of several other microRNAs [63, 64] (Table 1). Next-generation 
sequencing of FSHD myoblasts reported several additionally dysregulated microRNAs when 
compared with unaffected patient myoblasts [65] (Table 1).Additionally, a long-noncoding 
RNA (lncRNA)DBE-T has been implicated in the transcriptional activation of DUX4, and 
may also play a significant role in the promotion of the FSHD disease pathology [66]. Given 
the complexity of FSHD disease progression, epigenetic regulation by non-coding RNAs in 
FSHD muscles might offer an explanation for the unique dysregulation of myogenic and 
non-myogenic signaling pathways that occur in the FSHD disease state [67–69].
Limb girdle muscular dystrophies (LGMDs) and other neuromuscular 
diseases—Several other human neuromuscular diseases have strong etiopathologies 
associated with a dysregulation of microRNAs. The mouse model of laminin α2 chain 
(MDC1A) congenital muscular dystrophy showed significant alterations in expression levels 
of both the myomiRs and fibrosis-associated microRNAs [70]. LGMD2A is caused by a 
deficiency of the protease calpain-3 that results in muscle satellite cell defects, and a 
subsequent reduction in expression of the muscle-enriched myomiRs [71, 72]. Additionally, 
mouse models of LGMD2C, LGMD2D, and Emery-Dreifuss muscular dystrophy (EDMD) 
have revealed novel insights into the disease progression by identification of a unique 
microRNA diagnostic signatures throughout each diseases chronological progression [73]. 
Myotonic dystrophy is a multi-system disorder affecting skeletal muscle, brain, heart, and 
other organs commonly found in adults and is caused by either CTG (DM1; Myotonic 
dystrophy type 1) or CCTG (DM2; Myotonic dystrophy type 2) pathogenic repeat 
expansions of either DMPK (DM1) or ZNF9 (DM2) RNA transcripts [74, 75]. MicroRNA 
profiling of primary skeletal muscle myoblasts derived from DM1 and DM2 patients 
revealed unique diagnostic signatures of dysregulated microRNAs dependent on the type of 
myotonic dystrophy [76, 77] (Table 1). Several of these microRNA studies demonstrate the 
dynamic dysregulation of expression that can occur with various microRNAs that have 
known or unknown functions in skeletal muscle. One study of microRNAs dysregulated in 
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DM2 patient myoblasts demonstrated that miR-221, a microRNA shown to decrease in 
expression in the differentiation of quail myoblasts was significantly increased in total 
expression level [77, 78] (Table 1). Conversely, microRNA-378a, a microRNA shown to be a 
regulator of metabolism and obesity, was significantly deceased in DM2 patient myoblasts 
[77, 79] (Table 1). Interestingly, in the hearts of DM1 and DM2 patients the pri-miR-1 stem 
loop expression level increases in overall expression; however, the mature miR-1 sequence is 
overall reduced in comparison with unaffected patient hearts [80]. Conversely, mature miR-1 
is significantly increased in expression levels in DM1 patient primary myoblast cell lines 
when compared to unaffected control patient myoblast [76] (Table 1). The authors of the 
study showing decreased levels of miR-1 in DM1 and DM2 patient hearts (despite increased 
levels of pri-miR-1) demonstrate that miR-1 biogenesis is significantly altered due to the 
muscleblind protein (MBNL1) sequestration in the nucleus and dysregulation of microRNA 
interacting RNA-binding factors [80]. Thus, it is possible that there are different tissue-
specific post-transcriptional regulators of the microRNA processing machinery might be the 
causative mechanism for such disparate results of microRNA dysregulation in separate 
muscle tissues. These studies highlight the principle that the dysregulation of microRNAs in 
various muscle diseases can yield unique diagnostic signatures that are highly dependent on 
the causative disease mutation and potentially have tissue-specific effects.
Therapeutic inhibition of microRNAs in muscle diseases
Inhibition of microRNAs in vivo can be achieved via injection or oral delivery of anti-sense 
2′-O-methyl oligonucleotide inhibitors, antagomiRs, or locked nucleic acids (LNAs; a 
RNA-based molecule whose ribose moiety is modified with an extra bridge connecting the 
2′ oxygen and 4′ carbon) that target either the mature miRNA or the pri-miR precursor 
microRNA [81–85]. These antisense approaches work by blocking the target microRNA via 
direct binding, thereby inhibiting the microRNA from binding to the 3'UTR of target 
mRNAs (Fig. 2). Additional strategies include the use of multimerized microRNA 
complementary DNA sequences that act as “sponges” to block microRNA function by 
increasing the amount of bound microRNA to its complementary sequence [86]. It has 
already been shown that microRNA sponges can block cancer microRNAs (or “oncomiRs) 
from regulating their mRNA targets, thus having profound effects on tumor propagation and 
metastasis [87, 88]. Several groups have multimerized microRNA target sequences as 
another means of reducing the levels of unbound or circulating microRNAs. One study 
generated an AAV overexpressing miR-206 sponge consisting of multimerized miR-206 
binding sites, and demonstrated successful inhibition of miR-206 levels following injection 
into mice [89]. Furthermore, another group identified a small molecule inhibitor of the three 
myomiR function in vitro [90]. Inhibition of specific microRNAs has already shown 
therapeutic benefits in mouse models of cardiac hypertrophy [91, 92]. Thus, novel inhibitors 
(antisense or other methods) of microRNAs that are induced in specific neuromuscular 
diseases might hold promise in ameliorating specific aspects of the disease progression.
Strategies to overexpress microRNAs in muscle
Stable, long-term overexpression of specific-microRNAs in mammals has been 
demonstrated using Adeno-Associated Viral Vectors (AAVs) for several different diseases 
[93–95]. However, high-doses of microRNA-overexpressing AAV viral particles had been 
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previously shown to induce liver failure due to a saturation of the microRNA/shRNA 
processing machinery, thus making the virus delivery strategy, dosage, and serotype 
important in reducing any liver toxicity [96]. AAV serotypes AAV-6, -8, and -9 have been 
shown to be effective in the delivery of micro-dystrophin and/or other constructs to 
dystrophin-deficient skeletal and heart muscles [97–100]. Femoral AAV delivery of 
miR-196a into a mouse model of spinal and bulbar muscular atrophy (SBMA) was effective 
and therapeutically efficacious in targeting CELF2, a CUG-repeat binding protein that 
causes RNA toxicity by trapping it in skeletal muscles [24]. Other approaches such as the 
AAV over-expression of miR-669a in β-sarcoglycan (Sgcb)-null hearts showed long-term, 
and potent affects in restoring sarcomere organization and cardiac function [95]. More 
recently, efforts have been made to generate synthetic microRNA mimics with enhanced 
stability and reduced toxicity for in vivo animal use [101]. However, there is little known 
about the long-term effects and potency of these synthetic microRNA mimics, and more 
work is required to optimize their delivery in to muscle tissues.
Conclusions
There have been several recent studies that have attempted to manipulate the expression 
levels of microRNAs and more-importantly their mRNA targets in order to ameliorate 
neuromuscular disease pathologies. To suppress expression of the toxic DUX4 protein in 
FSHD, AAV vectors carrying artificial microRNA-based DUX4 open reading frame (ORF) 
inhibitors showed efficacy in a DUX4 overexpressing mouse model [102]. Manipulation of 
expression of the muscle-enriched microRNAs miR-206 and miR-486 in mouse models of 
DMD showed benefits in reducing fibrosis, promoting muscle regeneration, and improving 
overall muscle physiological strength [23, 25]. It is unclear whether or not these and other 
muscle-enriched microRNAs would have similar benefits in other mouse models of 
muscular dystrophy. As of to date, no specific human mutation in a microRNA sequence has 
been directly linked to a neuromuscular disease; however, there are some examples of 
microRNAs that when genetically manipulated result in muscle phenotypes similar to those 
found in human patients with neuromuscular diseases. MicroRNA-133a mutant mice 
develop centronuclear myopathy (CNM)-like symptoms due to miR-133a's direct regulation 
of the dynamin2 (DNM2) transcript [103]. Additionally, a naturally-occurring SNP mutation 
in the 3'UTR of the Myostatin (GDF8) gene generated a novel miR-1/206 binding site 
resulting in both a dramatic decrease in myostatin protein and a consequential increase in 
muscle size [104]. It is likely that with advances in next-generation sequencing technologies 
additional patient mutations in UTR's and perhaps even microRNA genomic sequences 
might directly be causative for neuromuscular diseases.
MicroRNAs may likely be used as biomarkers for testing the efficacy of a treatment for 
neuromuscular disease. For example, phosphorodiamidate morpholino oligonucleotide 
(PMO)-mediated dystrophin restoration therapy in mdx mice was able to correct the 
dysregulation of the myomiRs (miR-1, -133a/b, -206) to normal wild type levels in mouse 
serum indicating the dynamic nature of microRNA expression in neuromuscular disease 
[34]. Indeed, measurement of the disease progression severities such as the trait of loss of 
ambulation amongst DMD patients, may be quantitatively measured using serum microRNA 
biosignatures as useful predictor of drug benefits in DMD treatment patient cohorts [46]. 
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With a renewed emphasis towards non-invasive clinical biomarkers of neuromuscular 
disease therapies, microRNAs are an ideal biomarker to quantitatively measure the 
effectiveness of novel drug therapies (Fig. 1B). In conclusion, microRNAs are key players in 
the neuromuscular diseases, and can be exploited as therapeutic entry points for the 
treatment of disease due to their dynamic regulation of many cellular functions.
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AON Antisense oligonucleotide
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BMD Becker muscular dystrophy
CMD Congenital muscular dystrophy
CXMDJ Canine X-linked muscular dystrophy in Japan
DM1 Myotonic dystrophy type 1
DM2 Myotonic dystrophy type 2
DMD Duchenne muscular dystrophy
EDMD Emery-Dreifuss muscular dystrophy
FSHD Facioscapulohumeral muscular dystrophy
IBM Inclusion body myositis
LNA Locked nucleic acid
lncRNA Long, non-coding RNA
miR MicroRNA
MM Miyoshi myopathy
MO Morpholino
NM Nemaline myopathy
ORF Open reading frame
PM Polymyositis
PMO Phosphorodiamidate morpholino oligonucleotide
shRNA Short hairpin RNA
SRF Serum response factor
UTR Untranslated region
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Fig. 1. 
MicroRNAs can be isolated from serum and diseased muscles as diagnostic and quantitative 
biomarkers. Schematic showing the potential for the use of microRNAs both as diagnostic 
biomarkers (A) and quantitative biomarkers (B) in neuromuscular disease. A. Serum or a 
muscle biopsy can be taken from a patient with a known or undiagnosed neuromuscular 
disease. The sample is then analyzed for expression level and compared with known 
expression levels of specific microRNAs known to be dysregulated in particular 
neuromuscular diseases. B. An exon-skipping morpholino is used as a therapeutic 
intervention strategy to bypass the DNA deletion of exon 50 (red letter X) of protein-
encoding gene (e.g. dystrophin). The exon-skipping morpholino skips over exon 51 to 
restore the correct reading frame of the mRNA transcript. The resulting mRNA transcript is 
spliced together to restore function and/or reading frame of the mature mRNA when it will 
be translated into a mature protein by the ribosomal machinery. The microRNA levels are 
used as a non-evasive biomarker, and the microRNA biosignature is monitored for 
restoration to that of normal healthy muscle control expression levels.
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Fig. 2. 
Strategies to manipulate expression levels of microRNAs for the treatment of neuromuscular 
diseases. Therapies using Adeno-Associated Viral vectors (AAV) delivery to increase or 
decrease the expression levels of a specific microRNA that could be used to treat either 
primary or secondary consequences of the neuromuscular disease mutations and/or its 
disease-associated pathological symptoms. Synthetic approaches involving microRNA 
inhibitors (LNAs, MOs, or other AON molecules; blue seed loop) or microRNA sponges (or 
other “decoy molecules”) contain microRNA binding sites (red rectangles) and might be 
used to inhibit microRNA function via direct antisense inhibition thereby reducing the levels 
of endogenous microRNAs (red seed loop) in the serum or tissue. MicroRNA sponges or 
decoy molecules can be used to remove the amount of circulating or (“unbound”) 
microRNAs in a given tissue or from serum. Other synthetic molecules, such as microRNA 
mimics (red seed loop; MIMIC), might be used to mimic the function of endogenous 
microRNAs thereby suppressing the microRNA's intended mRNA target gene.
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Table 1
Several microRNAs known and validated as dysregulated in expression levels in different common 
neuromuscular disease. MicroRNA name, neuromuscular disease, sample tested, expression change (compared 
to unaffected controls), and reference are listed. For the myomiRs (miR-1, -133a/b, and 206) dysregulation 
was shown using serum from patients, except for DM1 (patient skeletal muscle biopsies). Note, only those 
publications using quantitative measurements (i.e. not only microRNA microarray fold changes such as real 
time quantitative PCR) are represented in the table
microRNA Neuromuscular disease Sample Expression change Reference(s)
miR-1 DMD, BMD, FSHD, DM1 serum, skeletal muscle biopsies (DM1) increased 18, 37, 46, 64, 73, 76
miR-21 MM, IBM PM skeletal muscle biopsies increased 16
miR-29b/c DM1 skeletal muscle biopsies decreased 76
miR-31 DMD skeletal muscle biopsies increased 38
miR-33 DM1 skeletal muscle biopsies decreased 76
miR-34a/b/c DM2 skeletal muscle biopsies increased 77
miR-125b DM2 skeletal muscle biopsies decreased 77
miR-133a/b DMD, BMD serum, skeletal muscle biopsies (DM1) increased 18, 37, 46, 64
miR-146b DM2 skeletal muscle biopsies increased 77
miR-193a/b DM2 skeletal muscle biopsies decreased 77
miR-199a DMD skeletal muscle biopsies increased 39
miR-206 DMD, BMD, DM1 serum, skeletal muscle biopsies (DM1) increased 18, 37, 46, 64, 73
miR-208a/b DMD; DM2 serum, skeletal muscle biopsies (DM2) increased 37, 77
miR-221 DM2 skeletal muscle biopsies increased 77
miR-335 DM1 skeletal muscle biopsies increased 76
miR-378a DMD; DM2 serum; skeletal muscle biopsies increased (DMD); decreased 
(DM2)
73, 77
miR-381 DM2 skeletal muscle biopsies increased 77
miR-411 FSHD skeletal muscle myoblasts increased 62
miR-486 DMD skeletal muscle biopsies decreased 40
miR-499 DMD serum increased 37
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